Advancements in NSCLC: In pursuit of a life for every patient

Improving NSCLC patient outcomes with targeted therapies

The latest episode of the EMJ podcast takes a deep dive into non-small cell lung cancer (NSCLC). Described as the most common type of lung cancer accounting for 80-90% of all lung cancer cases⁽¹⁾, NSCLC outcomes have historically been poor. Patients are often diagnosed at later stages when surgery and radiotherapy, still the primary treatment modalities, are less applicable. But the situation is improving as newer immunotherapies and targeted therapies are changing the landscape of advanced NSCLC treatment.

Listen in as two experts share their perspectives

Colin Lindsay, Clinical Senior Lecturer and Honorary Consultant in Thoracic Medical Oncology at The Christie is joined by Terri Conneran, a lung cancer survivor and founder of KRAS Kickers. Together they take listeners through the history of EGFR and KRAS inhibitors, discussing how diagnosis and treatment of NSCLC is changing from their unique perspectives.

Speakers:

Terri Conneran – Founder KRAS Kickers

Colin Lindsay – Clinical Senior Lecturer at The Christie

You won't want to miss the discussion.

References

1. Lindeman NI, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch. Pathol. Lab. Med. 2018;142:321-346.